Sagent’s Cefepime for injection will be available in 1g and 2g single dose vials. Sagent will begin marketing and shipping cefepime immediately. The introduction of Cefepime for injection marks the fourth product launch from Sagent’s pipeline of more than 200 products.
Cefepime hydrochloride for injection is indicated in the treatment of the following infections: pneumonia, empiric therapy for febrile neutropenic patients, urinary tract infections (including pyelonephritis), skin and skin structure infections, and intra-abdominal Infections.
Jeffrey Yordon, CEO, founder, and chairman of the board of Sagent, said: “The addition of Cefepime to our product portfolio, underscores our commitment to rapidly provide our customers and patients with a strong portfolio of injectable antibiotic products.”